ERBB2 and breast cancer: Our results pave the way for exploiting in vivo magnetic resonance imaging and MRS as a reliable and noninvasive clinical tool to detect intratumor lactate levels and thus selecting HER2‐positive BC patients who are more likely to benefit from anti‐HER2 treatments in both the adjuvant and metastatic treatment settings.